BioPorto
1.424
DKK
-0.14 %
Less than 1K followers
BIOPOR
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
-0.14%
-5.7%
-8.13%
-4.43%
-23.03%
+7.88%
-5.69%
-6.73%
-40.23%
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read moreMarket cap
611.85M DKK
Turnover
617.23K DKK
Revenue
36.24M
EBIT %
-208.2 %
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 2024-12-10
Financial calendar
11/4
2025
General meeting '25
8/5
2025
Interim report Q1'25
15/8
2025
Interim report Q2'25
All
Research
Webcasts
Press releases
ShowingAll content types
BioPorto announces the Annual Report for 2024
BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates
Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations
BioPorto A/S appoints new interim Chairman of the Board
Bioporto: Preliminary 2024 figures
Preliminary Financial Figures for the 2024 Fiscal Year
BioPorto commences process to appoint new Chair of the Board of Directors
Bioporto (One-pager): Emerging as a Diagnostic growth company
BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024
Grant of Warrants
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
Bioporto: Indgår partnerskab med Beckman Coulter om NGAL Tests til akut nyreskade
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
Bioporto: Wrap up from yesterday's event
BioPorto - Building the Global Commercial Platform
Bioporto: AKI adult study - insights
